

Micromedex® comprehensive evidence built upon robust editorial review methodologies

Solution Brief

Comprehensive clinical content for heightened confidence



We review world medical literature

- → Approximately 15,000 medical articles published each week
- → Approximately 8,500 journals monitored
- → Both high level and in-depth reviews performed regularly



In-house editorial team

 Clinically-trained editorial staff with expertise in research methodology

Our robust editorial processes support the comprehensive clinical evidence in Micromedex

Patient safety is a priority, and healthcare professionals look for clinically-relevant robust evidence to support critical decisions. Our in-house editorial staff undergo meticulous training, and the process used to develop the content in Micromedex has received accreditation from NICE.

Because our clinicians complete extensive evaluation and synthesis of the literature and assess information across multiple content areas, customers using Micromedex can be confident that our clinical content is designed to contain clinically accurate, relevant and consistent information.

Surveillance Evaluation Ongoing surveillance of Identification of methodologically worldwide biomedical literature solid literature on a topic and regulatory actions. from a variety of sources. and determination of clinical significance. Content creation Our specialists work across drug, disease, toxicology and patient education for consistency across all content sets Fortified evidence Internal and external review Content reviewed for clinical accuracy and relevance. Additional review by editorial board members for critical Final review and publish content areas.

Our procedures include

- → Multi-step editorial process and documented policies
- → Ongoing surveillance and critical evaluation of primary literature
- → In-house editorial team of clinically-trained editorial staff
- → Single editorial group and process ensures consistent content
- In-line referencing and supporting studies provides transparency
- ightarrow Consistent coverage of off-label and therapeutic uses
- → Inclusion of strength of efficacy and evidence ratings to aid clinicians in their treatment decisions



The National Institute for Health and Care Excellence (NICE) has accredited the process used by Merative to develop content used in its Micromedex solutions.¹

About Merative

Merative provides data and software for healthcare and government social services. With focused innovation and deep expertise, Merative works with providers, employers, health plans, governments, and life science companies to drive real progress. Merative helps clients orient information and insights around the people they serve to improve decision-making and performance. Merative, formerly IBM Watson Health, became a new standalone company as part of Francisco Partners in 2022. Learn more at merative.com.

Footnotes

¹The National Institute for Health and Care Excellence (NICE) is focused on reducing variation in the quality of care provided by the UK National Health Service. They promote the practice of evidence-based medicine to improve the quality of patient care. NICE develops clinical guidelines and quality standards to guide patient care in addition to accrediting processes employed by other guidance producers to promote improvement in healthcare quality. NICE has recently expanded their accreditation program to include processes utilized by clinical decision support providers. Accreditation indicates that the development processes are robust and transparent, leading to a trusted resource. NICE, through both their own guideline development efforts and their accreditation program, is seen as a globally trusted resource for clinicians and organizations seeking to improve the quality of patient care. Micromedex® received accreditation under Truven Health Analytics for content development processes for Micromedex Medication Management content on March 18, 2013 for a period of 5 years. We currently are accredited as Merative Micromedex. At present, the renewal process for NICE is suspended; however, Micromedex will retain our accreditation while the program is suspended. The Micromedex system is among the first CDS systems to achieve accreditation by NICE, indicating that clinicians can have confidence in the information provided to promote improved patient care.

© Copyright Merative US L.P. 2023 Merative 100 Phoenix Drive

Produced in the United States of America December 2023

Merative, the Merative logo and Micromedex are trademarks of Merative in the United States, other countries or both. All other company or product names are registered trademarks or trademarks of their respective companies.

This document is current as of the initial date of publication and may be changed by Merative at any time. Not all offerings are available in every country in which Merative operates.

The information in this document is provided "as is" without any warranty, express or implied, including without any warranties of merchantability, fitness for a particular purpose and any warranty or condition of non-infringement. Merative products are warranted according to the terms and conditions of the agreements under which they are provided.

The client is responsible for ensuring compliance with all applicable laws and regulations applicable to it. Merative does not provide legal advice or represent or warrant that its services or products will ensure that the client is in compliance with any law or regulation. The performance data and client examples cited are presented for illustrative purposes only. Actual performance results may vary depending on the specific configurations and operating conditions. It is the user's responsibility to evaluate and verify the operation of any other products or programs with Merative product and programs.

Statement of Good Security Practices: IT system security involves protecting systems and information through prevention, detection and response to improper access from within and outside your enterprise. Improper access can result in information being altered, destroyed, misappropriated or misused or can result in damage to or misuse of your systems, including for use in attacks on others. No IT system or product should be considered completely secure and no single product, service or security measure can be completely effective in preventing improper use or access. Merative systems, products and services are designed to be part of a lawful, comprehensive security approach, which will necessarily involve additional operational procedures, and may require other systems, products or services to be most effective. Merative does not warrant that any systems, product or services are immune from, or will make your enterprise immune from, the malicious or illegal conduct of any party.

